Postinfectious Guillain-Barre syndrome in a patient with methimazole-induced agranulocytosis

被引：3
作者：
Cho, Yoon Young
Joung, Ji Young
Jeong, Hyemin
Je, Dongmo
Hong, Yun Soo
Suh, Sunghwan
Kim, Sun Wook
机构：
[1] Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
[2] Division of Endocrinology and Metabolism, Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan
来源：
KOREAN JOURNAL OF INTERNAL MEDICINE | 2013年 / 28卷 / 06期
关键词：
SUSCEPTIBILITY; DISEASE;
D O I：
10.3904/kjim.2013.28.6.724
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Both Graves disease and Guillain-Barre syndrome (GBS) are autoimmune disorders caused by impaired self-tolerance mechanisms and triggered by interactions between genetic and environmental factors. GBS in patients who suffer from other autoimmune diseases is rarely reported, and the development of postinfectious GBS in a patient with Graves disease has not been. previously reported in the literature. Herein, we report a patient with Graves disease who developed postinfectious GBS during a course of methimazole-induced agranulocytosis.
引用
收藏
页码：724 / 727
页数：4
相关论文
共 9 条
[1]   Long term disability and social status change after Guillain-Barre syndrome [J].
Bersano, A ;
Carpo, M ;
Allaria, S ;
Franciotta, D ;
Citterio, A ;
Nobile-Orazio, E .
JOURNAL OF NEUROLOGY, 2006, 253 (02) :214-218
[2]   Graves' disease [J].
Brent, Gregory A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2594-2605
[3]   Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barre patients [J].
Geleijns, K ;
Jacobs, BC ;
Van Rijs, W ;
Tio-Gillen, AP ;
Laman, JD ;
van Doorn, PA .
JOURNAL OF NEUROIMMUNOLOGY, 2004, 150 (1-2) :132-138
[4]   HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome [J].
Geleijns, K ;
Schreuder, GMT ;
Jacobs, BC ;
Sintnicolaas, K ;
van Koningsveld, R ;
Meulstee, J ;
Laman, JD ;
van Doorn, PA .
NEUROLOGY, 2005, 64 (01) :44-49
[5]   Practice parameter: Immunotherapy for Guillain-Barre syndrome - Report of the quality standards subcommittee of the American Academy of Neurology [J].
Hughes, RAC ;
Wijdicks, EFM ;
Barohn, R ;
Benson, E ;
Cornblath, DR ;
Hahn, AF ;
Meythaler, JM ;
Miller, RG ;
Sladky, JT ;
Stevens, JC .
NEUROLOGY, 2003, 61 (06) :736-740
[6]  
Nappi G, 2000, NEUROL SCI, V21, P229
[7]  
van der Meche PG, 1992, NEW ENGL J MED, V326, P1123
[8]   Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome [J].
van Doorn, Pieter A. ;
Ruts, Liselotte ;
Jacobs, Bart C. .
LANCET NEUROLOGY, 2008, 7 (10) :939-950
[9]   Guillain-Barre syndrome: An update [J].
Vucic, Steve ;
Kiernan, Matthew C. ;
Cornblath, David R. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2009, 16 (06) :733-741
1